Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | POLQ | O75417 | 8/20 | 0.38 |
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | DAO | P14920 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13644756 | 0.91 | POLQ (0.46) | KIF11PDE2ACYP3A4CYP2D6POLQ | |
| SCHEMBL25530518 | 0.85 | CYP1A2 (0.41) | KIF11CYP2D6POLQCES2IDO1 | |
| SCHEMBL14275212 | 0.83 | CES2 (0.43) | KIF11PDE2ACYP3A4CYP2D6POLQ | |
| SCHEMBL102128 | 0.83 | CES2 (0.43) | KIF11PDE2ACYP3A4CYP2D6POLQ | |
| SCHEMBL19725441 | 0.81 | DAO (0.45) | KIF11PDE2AIDO1DAOTSHR | |
| SCHEMBL19170782 | 0.80 | KIF11 (0.47) | KIF11PDE2ACYP3A4CYP2D6CES2 | |
| SCHEMBL2600028 | 0.79 | IDO1 (0.54) | KIF11PDE2APOLQIDO1DAO | |
| SCHEMBL19224292 | 0.79 | CYP1A2 (0.42) | KIF11CYP3A4CYP2D6POLQTSHR | |
| SCHEMBL8220447 | 0.78 | PDE2A (0.49) | KIF11PDE2ACYP3A4CYP2D6POLQ | |
| SCHEMBL8225339 | 0.78 | CES2 (0.48) | KIF11PDE2ACYP3A4CYP2D6POLQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981930-B1 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981930-B1 | MAGL inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180134675-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
| US-20180134675-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134675-A1 | MAGL INHIBITORS | MAG, MAGI3, MGLL | KIF11 721/4885PDE2A 316/4885CYP3A4 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.